How Much Does Mounjaro Cost in District of Columbia?

Retail and Cash-Pay Pricing in D.C.

The sticker price for brand-name Mounjaro across District of Columbia retail pharmacies sits at $1,023 per month in 2026, matching the national wholesale acquisition cost set by Eli Lilly. This figure applies uniformly across all six tirzepatide dose strengths (2.5 mg through 15 mg) and covers a box of four single-dose pens, one injection per week.

Pharmacy-to-pharmacy variation in D.C. is minimal because the District's compact geography (68 square miles, roughly 120 retail pharmacies) compresses the kind of pricing spread seen in larger states. Patients filling without insurance should expect the full $1,023. Some pharmacy benefit aggregators and discount card platforms advertise lower cash prices, but confirmed D.C. transactions rarely dip below $970 for brand-name product.

For context on the drug's clinical value at this price point: in the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% from baseline versus 1.86% for semaglutide 1 mg over 40 weeks 1. That glycemic efficacy, paired with mean body-weight reduction of 12.4 kg, underpins formulary inclusion decisions across D.C. payers.

D.C. Medicaid Coverage

District of Columbia Medicaid (managed through AmeriHealth Caritas DC and other MCOs) covers Mounjaro with prior authorization. The PA requirement applies specifically to the type 2 diabetes indication. Weight management alone does not satisfy D.C. Medicaid's coverage criteria for Mounjaro as of early 2026.

PA approval typically requires documentation of: a confirmed type 2 diabetes diagnosis (HbA1c at or above 7%), failure or intolerance of metformin (unless contraindicated), and prescriber attestation that the patient has not achieved glycemic targets on current therapy. Approval periods run 6 to 12 months with renewal contingent on demonstrated HbA1c improvement.

D.C. Medicaid enrollees who receive approval pay $0 out of pocket. The District's Medicaid program covers approximately 260,000 residents (roughly 37% of the D.C. population), making this pathway significant in terms of population reach. Patients denied PA can file a formal appeal through the MCO's utilization review process, and D.C. regulations mandate a decision within 72 hours for standard appeals 2.

Commercial Insurance Coverage

Major commercial insurers operating in the District, including CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare, and Kaiser Permanente of the Mid-Atlantic, each maintain their own formulary placement for tirzepatide. Coverage patterns in D.C. break down roughly as follows:

CareFirst BCBS places Mounjaro on specialty tier (Tier 4 or 5) with step therapy requiring prior metformin use. Copay after step therapy: typically $75 to $150 per fill depending on plan design.

Aetna covers Mounjaro on preferred brand tier for type 2 diabetes in most employer-sponsored plans sold in D.C. Prior authorization is required. Plans purchased through DC Health Link (the District's ACA marketplace) may impose higher cost-sharing.

UnitedHealthcare requires PA and often mandates trial of a GLP-1 receptor agonist before approving tirzepatide. Specialty copay ranges from $100 to $200 per fill.

Kaiser Permanente Mid-Atlantic includes tirzepatide on formulary for type 2 diabetes with PA. Members using Kaiser's integrated pharmacy system pay a specialty medication copay, generally $50 to $100.

For all commercial plans, the critical variable is whether the employer or plan sponsor has carved out GLP-1/GIP agonists. An increasing number of self-funded employers nationwide excluded incretin-based therapies from coverage in 2025. D.C. residents on such plans face the full $1,023 unless they qualify for manufacturer assistance 3.

The Eli Lilly Savings Card

Eli Lilly's Mounjaro Savings Card remains the single most impactful cost-reduction tool for commercially insured D.C. residents. The program's 2026 terms: eligible patients with commercial insurance pay as little as $25 per monthly fill for up to 24 months. Maximum benefit caps at $573 per 30-day supply.

Eligibility requires:

• Active commercial (non-government) prescription drug insurance
• A valid Mounjaro prescription for an FDA-approved indication
• U.S. residency (D.C. qualifies)

The card does not apply to patients on Medicare Part D, Medicaid, TRICARE, or other federal/state programs. Patients on D.C. Medicaid are ineligible. Enrollment happens online or via the prescribing provider's office, and the card integrates directly at point of sale in D.C. pharmacies.

One functional note: if a patient's commercial plan outright excludes Mounjaro (no coverage determination at all), the savings card historically covered a larger portion. Lilly periodically adjusts these "no-coverage" terms, so D.C. patients in this situation should verify current benefit levels at activation 4.

Compounded Tirzepatide in District of Columbia

Compounded tirzepatide is available to D.C. residents through licensed 503A compounding pharmacies. These pharmacies operate under section 503A of the Federal Food, Drug, and Cosmetic Act, preparing patient-specific prescriptions based on an individual provider-patient relationship.

Average cost: $249 per month, roughly 75% below brand-name pricing.

The legal framework: D.C. permits 503A compounding when a licensed prescriber writes an individual prescription and the compounding pharmacy holds appropriate state licensure. The District of Columbia Board of Pharmacy oversees compounding operations within its jurisdiction. Out-of-state 503A pharmacies shipping into D.C. must comply with both their home state's pharmacy board requirements and federal 503A provisions.

The FDA's position on compounded tirzepatide shifted in 2024 when tirzepatide was removed from the drug shortage list. Following removal, FDA issued guidance asserting that 503A pharmacies should not compound copies of commercially available drugs absent a clinical difference justification. Enforcement, however, has been inconsistent. As of May 2026, multiple 503A pharmacies continue to compound tirzepatide for D.C. patients, citing ongoing access barriers (cost, insurance denials) as the patient-specific clinical need.

Patients considering compounded product should confirm: the pharmacy holds a valid license, uses USP 797-compliant sterile compounding facilities, sources tirzepatide base from an FDA-registered supplier, and provides certificates of analysis for potency and sterility. The SURPASS trials establishing tirzepatide's efficacy and safety profile used Lilly's manufactured product, not compounded formulations 1.

Telehealth Prescribing in D.C.

District of Columbia law permits telehealth prescribing of Mounjaro without geographic restriction within the District. The D.C. Department of Health extended pandemic-era telehealth flexibilities through permanent rulemaking, and tirzepatide (a non-controlled substance) faces no additional telehealth prescribing barriers.

Multiple telehealth platforms serve D.C. residents for GLP-1/GIP agonist prescriptions. Visits typically cost $50 to $150 for initial evaluation, with follow-ups at $30 to $75. Some platforms bundle the consultation fee into the medication cost (particularly those partnering with 503A pharmacies for compounded product).

Telehealth prescriptions for brand-name Mounjaro can be filled at any D.C. retail pharmacy, and the Eli Lilly savings card applies identically whether the prescription originates from an in-person or telehealth visit. D.C. prescribers must hold an active D.C. medical license or practice under the Interstate Medical Licensure Compact (of which D.C. is a member) 5.

Cost Comparison: Brand vs. Compounded vs. With Savings Card

Putting the three primary cost pathways side by side for a D.C. resident on 10 mg weekly dosing:

Brand-name, no insurance: $1,023/month ($12,276/year)

Brand-name with Lilly savings card (commercial insurance): $25/month ($300/year). This represents a 97.6% reduction from list price.

Compounded tirzepatide (503A): approximately $249/month ($2,988/year). No savings card applicable, but 75.7% below brand list.

D.C. Medicaid (approved PA): $0/month out of pocket.

Annual cost divergence between the cheapest insured pathway ($300) and uninsured cash pay ($12,276) exceeds $11,900. This gap explains why coverage determination and savings card enrollment are functionally the first clinical steps for D.C. providers initiating tirzepatide.

Strategies to Reduce Out-of-Pocket Cost

For D.C. residents facing high tirzepatide costs, a step-by-step approach:

Step 1: Verify formulary status. Call the number on the back of your insurance card. Ask specifically whether tirzepatide (Mounjaro) requires PA, step therapy, or is excluded entirely.

Step 2: Complete prior authorization. If covered with PA, ensure your provider submits documentation promptly. D.C. regulations require insurers to respond within 2 business days for non-urgent PAs.

Step 3: Activate the Lilly savings card. If commercially insured (even with high copay), register immediately. The card stacks on top of insurance adjudication.

Step 4: Appeal denials. D.C.'s external review process through the Department of Insurance, Securities, and Banking provides an independent review pathway if internal appeals fail.

Step 5: Evaluate compounded alternatives. If uninsured or insurance excludes the drug class entirely, compounded tirzepatide at $249/month offers the lowest verified price point available in D.C.

Step 6: Explore patient assistance. Eli Lilly's Lilly Cares program provides free Mounjaro to qualifying uninsured patients with household income at or below 400% of the federal poverty level 6.

Clinical Efficacy Supporting the Investment

The price discussion is incomplete without quantifying what tirzepatide delivers. In SURPASS-2, the head-to-head comparison against semaglutide 1 mg demonstrated tirzepatide's superiority across all three doses tested:

• Tirzepatide 5 mg: HbA1c reduction of 2.01% (vs. 1.86% for semaglutide)
• Tirzepatide 10 mg: HbA1c reduction of 2.24%
• Tirzepatide 15 mg: HbA1c reduction of 2.58%

Weight loss paralleled glycemic improvement: 7.6 kg, 9.3 kg, and 12.4 kg across the three tirzepatide arms versus 5.7 kg for semaglutide 1.

The dual GIP/GLP-1 receptor agonism mechanism differentiates tirzepatide from pure GLP-1 RAs. According to the FDA-approved prescribing information, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing complementary effects on insulin secretion, glucagon suppression, and appetite regulation 4.

For D.C. residents with type 2 diabetes and obesity (a common comorbidity in the District, where adult obesity prevalence is approximately 24.7% per CDC BRFSS data), the dual metabolic benefit may reduce downstream costs from cardiovascular events, renal progression, and diabetes-related hospitalizations 7.

D.C.-Specific Regulatory Considerations

The District of Columbia operates as both a city and a federal district, creating a unique regulatory environment. Key points for tirzepatide access:

Pharmacy licensure: The D.C. Board of Pharmacy licenses both in-District and out-of-state pharmacies. Compounding pharmacies shipping into D.C. need a non-resident pharmacy license.

Insurance regulation: The D.C. Department of Insurance, Securities, and Banking (DISB) regulates fully-insured plans sold in the District. Self-funded employer plans (governed by ERISA) fall outside DISB's jurisdiction. Approximately 60% of commercially insured D.C. workers are in self-funded plans.

Prescriber requirements: Any physician, nurse practitioner, or physician assistant with an active D.C. license (or compact privilege) can prescribe tirzepatide. No additional DEA registration is needed because tirzepatide is not a controlled substance.

DC Health Link (ACA marketplace): Plans sold on D.C.'s exchange must cover FDA-approved diabetes medications, though cost-sharing tiers and PA requirements vary by metal level. Bronze plans typically impose higher specialty copays than Gold or Platinum tiers 8.